Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria by Rabbani, N et al.
ORIGINAL ARTICLE
Effect of Irbesartan treatment on plasma and urinary markers
of protein damage in patients with type 2 diabetes
and microalbuminuria
Naila Rabbani • Antonysunil Adaikalakoteswari •
Kasper Rossing • Peter Rossing • Lise Tarnow •
Hans-Henrik Parving • Paul J. Thornalley
Received: 1 February 2011 / Accepted: 16 February 2011 / Published online: 8 March 2011
 Springer-Verlag 2011
Abstract The aim of this study was to assess the effect of
the angiotensin II receptor blocker Irbesartan on protein
damage by glycation, oxidation and nitration in patients
with type 2 diabetes and microalbuminuria. In a double-
masked randomised crossover trial of 52 hypertensive type
2 diabetic patients, antihypertensive treatment was
replaced with bendroflumethiazide. After 2-months wash-
out, patients were treated randomly with Irbesartan 300,
600, and 900 mg o.d., each dose for 2 months in a three-
way crossover study. Glycation, oxidation and nitration
adduct residues in plasma protein and related urinary free
adducts were determined by stable isotopic dilution anal-
ysis liquid chromatography–tandem mass spectrometry.
Treatment with Irbesartan decreased urinary excretion of
advanced glycation endproducts (AGEs)—methylglyoxal-
and glyoxal-derived hydroimidazolones, MG-H1 and
G-H1. Urinary AGEs were decreased by 30–32%. In
plasma protein, treatment with Irbesartan increased content
of glycation adducts Ne-fructosyl-lysine, AGEs Ne-car-
boxymethyl-lysine, Ne-carboxyethyl-lysine and pentosi-
dine, and also increased content of oxidation markers
N-formylkynurenine and dityrosine. This was attributed
to decreased clearance of plasma protein modified by
Ne-fructosyl-lysine and oxidative markers through the
glomerular filter tightened by Irbesartan treatment. Treat-
ment of patients with type 2 diabetes with Irbesartan
decreased urinary excretion of MG-H1, G-H1 and 3-NT,
which may result from decreased exposure to these AGEs.
This is likely achieved by blocking angiotensin II signal-
ling and related down-regulation of glyoxalase 1 and may
contribute to health benefits of Irbesartan therapy.
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Introduction
Proteins in physiological systems are susceptible to spon-
taneous modifications by glycation, oxidation and nitration.
Glycation of proteins is a complex series of parallel and
sequential reactions collectively called the Maillard reac-
tion. Early stage reactions are directed to lysine and
N-terminal amino acid residues leading to the formation of
the early glycation adduct, fructosyl-lysine (FL), and other
fructosamine derivatives. Later stage reactions produce
advanced glycation endproducts (AGEs). The most impor-
tant AGEs quantitatively are hydroimidazolones derived
from arginine residues modified by glyoxal, methylglyoxal
and 3-deoxyglucosone - G-H1, MG-H1 and 3DG-H (mix-
ture of 3 isomers), respectively (Ahmed et al. 2002). Other
important and widely studied AGEs are Ne-carboxymethyl-
lysine (CML), Ne-carboxyethyl-lysine (CEL) and crosslinks
glyoxal- and methylglyoxal-derived lysine dimers (GOLD
and MOLD, respectively) and pentosidine (PENT). Markers
of irreversible oxidative damage to proteins are dityro-
sine (DT) and N-formylkynurenine (NFK)—products of
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oxidation of tyrosine and tryptophan residues, respectively.
A widely studied marker of nitration damage to proteins is
3-NT (Thornalley 2006) (Fig. 1a–c). Glycated, oxidised
and nitrated proteins undergo cellular proteolysis leading to
the formation of glycated, oxidised and nitrated amino acids
called glycation, oxidation and nitration free adducts. These
are released into plasma, readily filtered in renal glomeruli
(molecular mass \ 500 Da) and, unless repaired or further
metabolised, are excreted in the urine (Fig. 1d).
Protein glycation, oxidation and nitration adduct resi-
dues in plasma protein are increased in experimental and
clinical diabetes (Ahmed et al. 2005; Karachalias et al.
2010). Some therapeutic options to reverse early stage
nephropathy in diabetes decrease the exposure to protein
AGE, oxidation and nitration adducts, as judged by
decreasing in urinary excretion of AGE, oxidation and
nitration free adducts (Karachalias et al. 2010). Inhibition
of the renin-angiotensin-aldosterone system (RAAS) by the
use of angiotensin II receptor blockers (ARBs) and
angiotensin converting enzyme inhibitors, usually com-
bined with diuretics, is considered a first-line treatment
modality for diabetic patients with microalbuminuria to
delay onset of renal insufficiency (American Diabetes
Association 2009). Irbesartan is a potent and selective
angiotensin II subtype 1 receptor ARB used in the treat-
ment of diabetic nephropathy (DN). In two large clinical
Fig. 1 Protein damage by
glycation, oxidation and
nitration. a Glycation adducts:
early glycation adduct FL and
advanced glycation
endproducts. b Oxidation
adducts, and c nitration adduct
3-NT. Adduct residues of
damaged proteins are shown.
The structure of one isomer of
3DG-H, 3DG-H1 (Ahmed et al.
2002). For the corresponding
free adducts at physiological
pH, the N-terminal amino group
is protonated –NH3
? and the
C-terminal carbonyl is a
carboxylate –CO2
- moiety.
d Multi-compartment model of
formation, proteolytic
processing and excretion of
proteins damaged by glycation,
oxidation and nitration in
diabetic nephropathy
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studies (Lewis et al. 2001; Parving et al. 2001), Irbesartan
exerted a renoprotective effect in hypertensive patients
with type 2 diabetes at both the early and later stages of
DN. These long-term studies using Irbesartan 300 mg o.d.
have demonstrated reduced progression to DN in micro-
albuminuric patients (Parving et al. 2001) and prevention
or delay of the combined endpoint of death, end stage renal
disease or doubling of creatinine in patients with DN
(Lewis et al. 2001). At least part of the beneficial effect of
ARBs in DN appears to be independent of hypotensive
action. Decrease of markers of low-grade inflammation
(C-reactive protein) and blood coagulation (fibrinogen)
have been found (Persson et al. 2006).
In this report, we describe the effect of Irbesartan
treatment of patients with type 2 diabetes and microalbu-
minuria on protein glycation, oxidation and nitration.
Plasma and urine samples were analysed retrospectively of
a trial to assess the dose-dependence of Irbesartan on uri-
nary albumin excretion (UAE), glomerular filtration rate
(GFR), blood pressure and other conventional biochemical
and clinical variables (Rossing et al. 2005). Plasma protein
content of glycation, oxidation and nitration adducts and
urinary excretion of protein glycation, oxidation and
nitration adducts were quantified by stable isotopic dilution
analysis liquid chromatography with tandem mass spec-
trometric detection (LC–MS/MS).
Materials and methods
Patients and trial design
Patient recruitment, study design and clinical procedures
were described previously (Rossing et al. 2005). Briefly, all
patients were recruited from the Steno Diabetes Center.
The study was a double-masked randomised three-way
crossover trial including 52 (41 males) hypertensive type 2
diabetic patients with microalbuminuria on ongoing anti-
hypertensive medication randomly assigned to crossover
subgroups 1, 2 and 3 of 17, 17 and 18 patients, respec-
tively. At inclusion, antihypertensive treatment was dis-
continued and replaced with bendroflumethiazide, 5 mg
once daily, for the entire study. Following 2-months wash-
out (baseline), patients were treated randomly with
Irbesartan 300, 600, and 900 mg once daily, each dose for
2 months. Endpoints evaluated at the end of each study
period included UAE (mean of three 24-h collections),
24-h ambulatory blood pressure and GFR (chromium 51
ethylenediaminetetraacetic acid method). Blood pressure,
glycated haemoglobin HbA1c, total cholesterol, LDL,
VLDL, HDL and triglycerides were reported previously
(Rossing et al. 2005). All doses of Irbesartan significantly
decreased UAE, ambulatory blood pressure, and GFR from
baseline; UAE was decreased more by Irbesartan 900 mg
compared to other doses (Rossing et al. 2005). The local
ethical committee approved the study, and all patients gave
their written informed consent to participate in the study
after the nature of the study had been explained. The
study was performed in accordance with the Helsinki
Declaration.
Protein damage marker analysis
Protein glycation, oxidation and nitration adducts were
determined by LC–MS/MS with quantitation by stable
isotopic dilution analysis (Thornalley et al. 2003). Opti-
mised conditions for analyte detection are given in
Table 1. Twelve analytes were determined: FL, CML,
CEL, G-H1, MG-H1, 3DG-H, GOLD, MOLD, NFK, DT
and 3-NT by stable isotopic dilution analysis LC–MS/MS,
and PENT by concurrent fluorescence detection (excita-
tion wavelength 320 nm, emission wavelength 365 nm).
They were quantified by reference to calibration curve
response of authentic standard. LC–MS/MS and fluores-
cence detection was performed with a Waters Acquity
UPLC system with Acquity fluorescence detector and
Quattro Premier XE tandem mass spectrometer. Urinary
glycation, oxidation and nitration free adducts were
determined by direct analysis of urine ultrafiltrates (3 kDa
cut-off). Glycation, oxidation and nitration adduct residues
of plasma protein were determined after exhaustive
enzymatic hydrolysis by consecutive incubation with
pepsin, pronase E, and finally aminopeptidase and proli-
dase, under nitrogen (Thornalley et al. 2003). Plasma was
prepared immediately after blood collection. Twenty-four-
hour urine samples were collected at ambient temperature
without additives. Both were then stored at -80C until
analysis. Previous validation studies have shown that
protein damage marker free adduct contents do not change
significantly under these collection and storage conditions
(Thornalley et al. 2003). Sample identity was blinded from
the investigator.
Statistical analysis
Data are mean ± SD for parametric data and median
(upper–lower quartile) for non-parametric data. Signifi-
cance of difference between mean changes was assessed by
Student’s paired t test and two-way ANOVA. Significance
of difference between median changes was assessed by
Wilcoxon’s signed ranks test and Friedman’s two-way
analysis of variance. Crossover subgroup data were
compared by one-way ANOVA and Kruskal–Wallis test.
Correlation analysis was by the Spearman non-parametric
method. Bonferroni correction was applied for a 12 vari-
able composite analysis of protein damage markers.
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Results
Clinical characteristics of type 2 diabetic patients
with microalbuminuria during treatment
with Irbesartan
Clinical characteristics at baseline and during study have
previously been published (Rossing et al. 2005) but are
summarised in Table 2. Mean UAE was decreased by
41–51% and GFR by 5–8% by Irbesartan treatment. Mean
systolic blood pressure (BP) was decreased from 140 to
130–132 mmHg and mean diastolic BP was decreased
from 77 to 70–71 mmHg by Irbesartan treatment. There
were minor increases of plasma creatinine and HDL and
minor decreases in fasting plasma glucose, total cholesterol
and LDL cholesterol during Irbesartan treatment.
Protein damage markers
Patients with type 2 diabetes and microalbuminuria treated
with Irbesartan had no significant change in plasma protein
contents of AGEs MG-H1, G-H1, GOLD and MOLD, and
also of 3-NT. Irbesartan treatment produced a small
decrease in plasma protein content of 3DG-H; median
plasma protein 3DG-H-Irbesartan treatment 0.21–0.22
mmol/mol arg, baseline 0.25 mmol/mol arg (P \ 0.001).
In contrast, plasma protein FL content was increased by
66–72% from baseline, independent of Irbesartan dose and
plasma protein contents of CML, CEL and PENT were
increased by 51–62, 149–180 and 34–43%, respectively,
with Irbesartan treatment independent of dose. For protein
oxidation markers, the plasma protein contents of NFK and
DT were increased 40–60 and 60–81%, respectively, by
Irbesartan therapy (Table 3; Fig. 2a–f).
For urinary excretion of protein damage markers, there
was no significant change in urinary excretions of FL,
CML, CEL, 3DG-H, GOLD, MOLD, PENT and NFK free
adducts with Irbesartan treatment (Table 3). Urinary
excretion of the major AGE, hydroimidazolone MG-H1
free adduct, was decreased 31–32% by Irbesartan, inde-
pendent of dose (Fig. 3a). Excretion of G-H1 was
decreased 35–45% by Irbesartan treatment independent of
dose (Fig. 3b). Together, excretion of MG-H1 and G-H1
was decreased by 30–32% by Irbesartan treatment inde-
pendent of dose. For oxidative markers, urinary excretion
of DT was increased by 25% and 3-NT was decreased 44%
Table 1 Mass spectrometric multiple reaction monitoring detection of protein glycation, oxidation and nitration adducts
Analyte group Analyte Parent ion
(Da)
Fragment ion
(Da)
CE
(eV)
CV
(V)
Neutral fragment loss(es) Internal standard
Amino acids Arg 175.1 70.1 24 30 H2CO2, NH2C(=NH)NH2 [guanidino-
15N2]Arg
Lys 147.1 84.1 18 10 H2CO2, NH3 [U-
13C6]Lys
Tyrosine 181.9 136.0 16 20 H2CO2 [ring-
2H4]Tyrosine
Tryptophan 205.2 158.8 20 20 H2CO2 [U-
15N2]Trp
Glycation adduct FL 291.0 84.1 32 35 H2CO2, fructosylamine [4,4,5,5-
2H4]FL
G-H1a 215.0 100.2 18 25 NH2CH(CO2H)CH2CH=CH2 [ring-
15N2]G-H1
MG-H1a 229.0 114.0 18 20 NH2CH(CO2H)CH2CH=CH2 [
15N2]-MG-H1
3DG-Ha 319.0 115.2 25 45 NH2CH(CO2H)CH2CH=CH2 [
15N2]-3DG-H
CML 204.9 84.1 19 24 NH2CH2CO2H, H2CO2 [U-
13C6]-CML
CEL 219.0 84.1 20 27 NH2CH(CH3)CO2H, H2CO2 [U-
13C6]-CEL
GOLD 327.1 84.1 31 44 NH2CH(CO2H)CH2CH2CH2CH2
NN , H2CO2
[4,4,5,5,40,40,50,50-2H8]-GOLD
MOLD 341.0 84.1 33 44 NH2CH(CO2H)CH2CH2CH2CH2
NN
CH3
, H2CO2
[4,4,5,5,40,40,50,50-2H8]-MOLD
Oxidation adduct Dityrosine 361.0 315.0 22 35 H2CO2 [ring-
2H6]Dityrosine
NFK 237.0 191.1 11 20 H2CO2 [U-
2N15]NFK
Nitration adduct 3-NT 226.9 180.9 18 25 H2CO2 [ring-
2H3]3-NT
a For hydroimidazolones, structural isomer-1 is denoted, although for 3DG-H detection, structural isomers 3DG-H1, 3DG-H2 and 3DG-H3 are
all detected (Thornalley et al. 2003). Molecular and fragment ion detection was optimised to ±0.1 Da and collision energy and cone voltage to
±1 eV and 1 V, respectively. Other instrument settings were: capillary voltage 1.00 kV, source temperature 120C, desolvation gas temperature
350C, desolvation gas flow rate 898 l/h, cone gas flow rate 87 l/h, collision gas (argon) pressure 5.0 9 10-3 mbar, mobile phase flow rate
0.2 ml/min. Anlaytes were detection with a Quattro Premier XE tandem mass spectrometer (Waters, Manchester, UK)
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but only at the 300 mg o.d. Irbesartan dose with borderline
significance (P \ 0.05, Friedman) (Fig. 3c, d).
Correlation of protein damage and clinical variables was
investigated for patients at baseline and after 300 mg o.d.
Irbesartan treatment; correlations were similar for other
Irbesartan doses. There were relatively few correlations of
plasma protein damage markers at baseline and with Ir-
besartan treatment. Only plasma protein FL correlated with
HbA1c (Table 4). There were a greater number of signifi-
cant correlations of urinary protein damage marker free
adducts at baseline and an increase in positive correlations
with Irbesartan treatment. Urinary CML, CEL, MG-H1 and
PENT correlated positively with urinary FL at baseline
with correlations with CML and MG-H1 remaining with
Irbesartan treatment (Table 5).
Surprisingly, there were no correlations of plasma pro-
tein damage markers or urinary free adducts with GFR and
UAE at baseline and only correlation of urinary NFK
(r = 0.48, P \ 0.01) and 3-NT (r = 0.41, P \ 0.05) with
GFR after Irbesartan treatment. Systolic blood pressure
correlated positively with plasma protein MOLD
(r = 0.46, P \ 0.05) and negatively with plasma protein
3-NT (r = -0.39, P \ 0.05). After Irbesartan therapy,
these correlations were lost.
Table 2 Clinical variables of patients with type 2 diabetes and microalbuminuria at baseline and after Irbesartan treatment
Variable Baseline Irbesartan treatment
300 mg o.d. 600 mg o.d. 900 mg o.d.
24 h UAE (lg/min) 93 (72–118) 45 (40–50)*** 47 (43–53)*** 38 (34–43)***
GFR (ml/min/1.73 m2) 103 ± 3 98 ± 3* 95 ± 3*** 95 ± 3***
Plasma creatinine (lM) 94.5 ± 2.0 97.2 ± 2.1* 98.2 ± 2.1** 96.9 ± 2.3**
Fasting glucose (mM) 10.4 ± 0.4 9.6 ± 0.3** 9.7 ± 0.4 9.7 ± 0.3*
HbA1c (%) 8.4 ± 0.2 8.2 ± 0.2 8.3 ± 0.2 8.2 ± 0.2
Total cholesterol (mM) 4.32 ± 0.14 4.04 ± 0.14* 4.18 ± 0.10* 4.00 ± 0.09*
LDL (mM) 2.61 ± 0.11 1.88 ± 0.09* 2.03 ± 0.09* 1.94 ± 0.09*
HDL (mM) 1.21 ± 0.05 1.25 ± 0.05* 1.25 ± 0.05* 1.24 ± 0.05*
Triglyceride (mM) 2.05 ± 0.20 1.87 ± 0.18 1.94 ± 1.17 1.81 ± 0.17
Systolic BP (mmHg) 140 ± 2 132 ± 2*** 130 ± 2*** 130 ± 2***
Diastolic BP (mmHg) 77 ± 1 71 ± 1*** 70 ± 1*** 70 ± 1***
Data are mean ± SEM except for UAE which are geometric mean (95% CI)
Significance: *P \ 0.05, **P \ 0.01 and ***P \ 0.001 with respect to baseline
Table 3 Protein damage markers in plasma protein and urine of patients with type 2 diabetes and microalbuminuria at baseline
Plasma protein
damage marker
Type 2 diabetic patients
with microalbuminuria
at baseline (n = 52)
Urinary protein
damage marker free
adduct (lmol/24 h)
Type 2 diabetic patients
with microalbuminuria
at baseline (n = 52)
FL (mmol/mol lys) 6.91 ± 1.29 FL 145 (92–206)
CML (mmol/mol lys) 0.052 ± 0.014 CML 10.3 (7.3–14.9)
CEL (mmol/mol lys) 0.008 (0.005–0.021) CEL 3.8 (2.8–4.6)
G-H1 (mmol/mol arg) 0.075 (0.053–0.145) G-H1 6.36 (4.22–11.63)
MG-H1 (mmol/mol arg) 0.40 (0.34–0.44) MG-H1 118 (77–157)
3DG-H (mmol/mol arg) 0.25 (0.23–0.28) 3DG-H 5.43 (4.03–7.38)
GOLD (mmol/mol lys) 0.00034 (0.00019–0.0004) GOLD 0.0061 (0.0037–0.0104)
MOLD (mmol/mol lys) 0.0034 (0.0026–0.0107) MOLD 0.126 (0.084–0.202)
PENT (mmol/mol lys) 0.0012 (0.0010–0.0015) PENT 0.066 (0.033–0.214)
NFK (mmol/mol trp) 0.38 (0.027–0.057) NFK 0.52 (0.40–0.80)
DT (mmol/mol tyr) 0.0022 (0.0019–0.0030) DT 0.0022 (0.0019–0.0030)
3-NT (mmol/mol tyr) 0.0071 (0.0034–0.0095) 3-NT 0.058 (0.023–0.162)
Data are mean ± SD or median (lower–upper quartile)
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Carryover effects of Irbesartan treatment on protein
damage marker analysis
Carryover effects, the effect of prior Irbesartan treatment in
the second and third crossover periods, were examined by
comparing plasma protein and urinary protein damage
analyte levels in patient crossover subgroups 1–3 receiving
300 mg o.d. Irbesartan in successive 10-week treatment
periods. Analytes showing significant difference over the
three treatment periods with the 300 mg o.d. dose were:
Fig. 2 Effect of Irbesartan dose on plasma protein glycation and
oxidation adducts. a FL, b CML, c CEL, d PENT, e NFK and f DT.
Data are normalised to the amino acid residue modified and are
median (upper–lower quartile) except mean ± SD for a and
b. Significance: *P \ 0.05, **P \ 0.01 and ***P \ 0.001 with
respect to baseline (Wilcoxon’s signed ranks test or paired t test
(a and b) with Bonferroni correction)
Fig. 3 Effect of Irbesartan dose
on urinary free adduct excretion
of glycation, oxidation and
nitration adducts. a MG-H1,
b G-H1, c DT and d 3-NT.
Plasma protein adduct data are
normalised to the amino acid
residue modified. Data are
median (upper–lower quartile).
Significance: *P \ 0.05,
**P \ 0.01 and ***P \ 0.001
with respect to baseline
(Wilcoxon’s signed ranks test
with Bonferroni correction)
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plasma protein markers—CML, CEL, MG-H1, pentosidine
and 3-NT, and urinary CEL (P \ 0.05; Kruskal–Wallis).
The variation of these analytes over the three treatment
periods compared to the related baseline level was exam-
ined (Fig. 4). This revealed that plasma protein CML was
increased modestly and CEL unchanged in the first treat-
ment period and increased further in the second and third
treatment periods, where patients had received higher dose
Irbesartan in the previous treatment periods (Fig. 4a, b).
Plasma protein content of MG-H1 was decreased in the
initial treatment period but not thereafter (Fig. 4c). Plasma
protein contents of pentosidine and 3-NT were increased in
the initial treatment period but not thereafter, with plasma
protein 3-NT content decreasing below baseline in the third
treatment period (Fig. 4d, e). To eliminate carryover
effects and to examine the dependence of change on
Table 4 Correlation triangle of glycemic control and plasma protein damage-related variables at baseline (a) and after Irbesartan treatment (b)
a HbA1c             
FL 0.56c            
AGE 
CML             
CEL             
G-H1              
MG-H1         
3DG-H 0.49b 0.46b     
GOLD    0.52b        
MOLD        
PENT    0.63c    
−0.48b
Oxidative
damage 
NFK 0.42a  0.64c
−0.52b
DT   0.50b
3-NT   0.43a      0.57c 0.58c –0.53b
 Analyte HbA1c FL CML CEL G-H1 MG-H1 3DG-H GOLD MOLD PENT NFK DT 3-NT 
 egamad evitadixO EGA
b HbA1c           
FL 0.58c          
AGE 
CML            
CEL   0.52b         
MG-H1   0.45b 0.70c        
GOLD            
MOLD      0.58c      
PENT     
−0.64c     
Oxidative
damage 
NFK   0.49b         
DT     
−0.55c   0.43c
3-NT   
−0.42a −0.47b −0.72c   0.64c  0.60c
 Analyte HbA1c FL CML CEL MG-H1 GOLD MOLD PENT NFK DT 3-NT 
 egamad evitadixO EGA
Data are correlation coefficients (Spearman) with significance: aP \ 0.05, bP \ 0.01 and cP \ 0.001
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Irbesartan dose on protein damage markers, the levels of all
analytes for all three doses of Irbesartan were compared to
baseline levels at the end of the first dosing period.
Treatment with Irbesartan increased plasma protein con-
tents of FL, CML, pentosidine and dityrosine and
decreased plasma protein content of MG-H1 at the 300 mg
o.d. dose (Fig. 5). Overall, the effect was independent of
Irbesartan dose. For urinary protein damage markers, there
was no significant effect of Irbesartan treatment after the
first treatment period for patient crossover subgroups.
Since the effects of Irbesartan were independent of dose,
the patient subgroups were combined and plasma protein
Table 5 Correlation triangle of glycemic control and urinary protein damage-related variables at baseline (a) and after Irbesartan treatment (b)
a FL            
AGE 
CML 0.62c           
CEL 0.54c 0.74c           
G-H1        
MG-H1 0.48b 0.46b 0.64c     
3DG-H  0.64c     
GOLD   0.44a        
MOLD   0.59c 0.52c 0.58c 0.44a 0.44a     
PENT 0.47b   
−0.4
3a
   
Oxidative
markers 
NFK  0.42a 0.50b 0.55c 0.64c  0.42a
DT  0.41a 0.52b   
3-NT    
−0.66c     0.52b   
 Analyte FL CML CEL G-H1 MG-H1 3DG-H GOLD MOLD PENT NFK DT 3-NT 
 srekram evitadixO EGA   
b FL            
AGE 
CML 0.53c           
CEL  0.61c          
G-H1  0.61c 0.63c         
MG-H1 0.53c 0.59c 0.53c 0.70c        
3DG-H  0.47b 0.44a 0.60c 0.57c       
GOLD 0.45b 0.58c  0.48b 0.42a 0.46b      
MOLD  0.63c 0.58c 0.69c 0.67c 0.62c 0.63c     
Oxidative
markers 
NFK   0.43a 0.43a      
DT  0.51b 0.50b 0.64c 0.41a 0.42a 0.49b 0.54c
3-NT   0.41a      0.41a 0.49b
 Analyte FL CML CEL G-H1 MG-H1 3DG-H GOLD MOLD NFK DT 3-NT 
 srekram evitadixO EGA   
Data are correlation coefficients (Spearman) with significance: aP \ 0.05, bP \ 0.01 and cP \ 0.001
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content of protein damage adduct residues and urinary
fluxes of protein damage free adducts were re-examined.
This revealed that for the first treatment period (any dose)
where carryover effects do not apply Irbesartan produced
increases in FL, CML, CEL, PENT and DT adduct residues
and decreased 3DG-H adduct residue of plasma protein and
decreased urinary flux of G-H1, MG-H1 and 3-NT free
adducts (Figs. 6, 7).
Fig. 4 Effect of crossover treatment period on the response of protein
damage markers to Irbesartan treatment. a CML, b CEL, c MG-H1,
d PENT and e 3-NT residue content of plasma protein—data are
normalised to the amino acid residue modified. f CEL urinary free
adduct: flux per 24 h. Bars: unfilled baseline, filled 300 mg o.d.
Irbesartan (mean, error bar is SD). Crossover periods 1, 2 and 3
occurred after 10, 20 and 30 weeks Irbesartan treatment and had study
subgroups of 17, 17 and 18 patients, respectively. Significance:
*P \ 0.05, **P \ 0.01 and ***P \ 0.001 with respect to baseline
(paired t test with Bonferroni correction)
Fig. 5 Effect of Irbesartan dose on protein damage markers in the
first treatment period. a FL, b CML, c MG-H1, d PENT and e DT
residue content of plasma protein—data are normalised to the amino
acid residue modified. Bars: unfilled baseline, filled Irbesartan
treatment (mean; error bar is SD with n = 17 for 300 and 600 mg
o.d. dose, and n = 18 for 900 mg o.d. dose). Significance: *P \ 0.05,
**P \ 0.01 and ***P \ 0.001 with respect to baseline (paired t test
with Bonferroni correction)
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Discussion
In this study, we found that treatment of patients with type
2 diabetes with Irbesartan increased plasma protein FL
residues. This increase was independent of change in gly-
caemic control since HbA1c was unchanged and there was
minor decrease in fasting plasma glucose. This effect was
maintained when carryover effects were excluded. The
explanation for this may be related to the effect of Irbe-
sartan on the glomerular filter. Irbesartan treatment tightens
the glomerular filter and thereby decreases protein leakage
into glomerular filtrate. The glomerular filter has been
found to exhibit preferential retention of FL-modified
albumin in patients with type 2 diabetes (Cha et al. 1991).
This may be exacerbated further by Irbesartan. This effect
of Irbesartan may be expected as the mean molecular size
of FL-modified albumin, as judged by Stoke’s radii, is
greater than that of the mean glomerular filter pore size of
patients treated with Irbesartan (4.2 vs. 3.8 nm) (Remuzzi
et al. 1999; Sattarahmady et al. 2007). Glomerular transit
of FL-modified albumin may therefore be impaired with
Irbesartan therapy. In contrast, modification of albumin by
methylglyoxal and glyoxal forming MG-H1 and G-H1,
respectively, did not increase the Stoke’s radius of albumin
(Sattarahmady et al. 2007; Westwood and Thornalley
1995) and MG-H1 and G-H1 content of plasma protein was
not increased with Irbesartan treatment.
Increase of plasma protein FL content independent of
change in HbA1c uncouples assessment of glycaemic
control by HbA1c and plasma fructosamine. The difference
between measured HbA1c and predicted HbA1c—the latter
based on measurement of plasma fructosamine and the
Fig. 6 Effect of all Irbesartan (all doses combined) on protein
damage markers of plasma protein in the first treatment period. a FL,
b CML, c CEL, d DG-H, e PENT and f DT. Data are normalised to
the amino acid residue modified. Data are mean ± SD. Significance:
**P \ 0.01 and ***P \ 0.001 with respect to baseline (paired t test
with Bonferroni correction)
Fig. 7 Effect of all Irbesartan (all doses combined) on protein
damage markers of urine in the first treatment period. a G-H1, b MG-
H1 and c PENT. Data are urinary flux (lmol per 24 h); mean ± SD
for a and b and median (upper–lower quartile) for c. Significance:
*P \ 0.05, and ***P \ 0.001 with respect to baseline [paired t test
with Bonferroni correction, (a, b), Wilcoxon’s signed ranks test (c)]
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usual linear relationship between HbA1c and plasma fruc-
tosamine—has been called the ‘‘glycosylation gap’’ and is
increased in DN (Cohen et al. 2003). The increase of
plasma FL with Irbesartan treatment herein suggests that
therapeutic agents tightening the glomerular filter may also
contribute to the glycosylation gap. This deserves further
investigation.
An expected consequence of increased FL content of
plasma protein for patients with Irbesartan treatment is
increased rate of degradation of FL to CML and CEL
residues in plasma protein, leading to increased urinary
excretion of CML and CEL free adducts. FL degrades
oxidatively to CML and is a minor source of methylgly-
oxal—the precursor of CEL (Ahmed et al. 1986;
Thornalley et al. 1999). Increased rate of FL degradation
may also lead to increased formation of pentosidine (Dyer
et al. 1991). This may explain the concurrent increase of
plasma protein CML, CEL and pentosidine with increased
FL with Irbesartan therapy. Irbesartan treatment also pro-
duced ca. twofold increases in NFK and DT adduct content
of plasma protein. This suggests that NFK and DT-modi-
fied plasma protein may also be retained by the tightened
glomerular filter with Irbesartan treatment and/or the rate
of NFK and DT formation was increased by increased
oxidation degradation of plasma protein FL.
In this study we found, for the first time, that Irbesartan
therapy produced significant decreases in urinary excretion
of selected AGEs MG-H1 and G-H1 and 3-NT. This was
also found when carryover effects were excluded (see
later). In diabetes, urinary AGE and 3-NT free adducts are
thought to originate mainly from proteolysis of AGE-
modified and nitrated tissue proteins, respectively
(Karachalias et al. 2010). Urinary excretion of protein
damage free adducts is related to total body exposure to
protein damage, relating to flux of formation of glycation,
oxidation and nitration adducts within tissues and body
fluids except where there is significant sourcing of free
adducts from others sources and/or significant metabolism
and repair of free adducts (Karachalias et al. 2010;
Thornalley et al. 2003). Repair is significant for FL free
adduct, undergoing de-glycation to lysine by fructosamine
3-phosphokinase (Szwergold et al. 2001), and metabolism
significant for 3-NT to 3-nitro-4-hydroxyphenylacetic acid
and 3-nitro-4-hydroxyphenylacetic acid (Ohshima et al.
1990). These changes may therefore reflect decreased
exposure to AGEs, particularly MG-H1 and G-H1, and
protein nitration damage that likely contribute to health
benefits of Irbesartan. Decrease in urinary MG-H1 and
G-H1 is consistent with the recently discovered involve-
ment of angiotensin blockade in regulation of glyoxalase 1
(Miller et al. 2010) which detoxifies methylglyoxal and
glyoxal (Thornalley 1993). The flux of urinary MG-H1 free
adduct is sourced mainly from the proteolysis of MG-H1
modified proteins in tissues (Karachalias et al. 2010).
Increase in glyoxalase 1 expression in tissues will decrease
tissue levels of methylglyoxal, decreasing MG-H1 residue
content of tissues proteins and export for MG-H1 free
adduct there from following proteolysis. This may occur
without decrease in plasma protein MG-H1 content,
although patients receiving 300 mg o.d. Irbesartan in the
first phase of the crossover study had decreased plasma
protein MG-H1 residue content with respect to baseline
level (Fig. 4c).
A high flux of MG-H1 urinary free adduct excretion was
found for patients with type 2 diabetes at baseline herein.
This was found previously in patients with type 1 diabetes
(Ahmed et al. 2005) and reflects the relatively high levels
of protein damage caused by glycation by methylglyoxal in
clinical diabetes (Thornalley 2005). Reversal of increased
urinary excretion of MG-H1 by Irbesartan reflects
decreased formation of MG-H1 in tissues and body fluids
(Karachalias et al. 2010). Accumulation of MG-H1 in
vascular cell mitochondrial proteins in diabetes is associ-
ated with increased mitochondrial dysfunction, oxidative
stress and related metabolic dysfunction (Rosca et al.
2005). Increased formation of MG-H1 in vascular extra-
cellular matrix type IV collagen was associated with
endothelial detachment (Dobler et al. 2006)—a risk pre-
dictor of cardiovascular disease (Segal et al. 2002). Partial
reversal of MG-H1 formation by Irbesartan therapy is,
therefore, of likely pharmacological benefit.
There were very few correlations of protein damage
markers with GFR and UAE. The lack of correlation with
GFR may be due to the small 4–8% decrease in GFR from
baseline induced by Irbesartan (Rossing et al. 2005) and
limited glomerular filtration of most damaged plasma
proteins (Rabbani et al. 2007). The lack of correlation with
UAE is consistent with limited effect of increased inter-
action of albumin with the renal tubular epithelium on
plasma protein glycation or tissue protein glycation and
proteolysis. Irbesartan therapy changed multiple correla-
tions of protein damage markers, however. In future studies
of protein damage in DN it will be important to carefully
match RAAS blockade therapy in patient study groups as
ARB therapy may affect the protein damage assessment
outcomes, particularly in correlation analysis.
A potentially confounding factor in this crossover study
is the effect of carryover responses to Irbesartan from prior
treatment periods. This may be expected particularly for
protein damage markers of plasma protein where the half-
life of the major plasma protein, albumin, is ca. 20 days
(Peters 1996). There was no washout period in this three-
way crossover design but rather a 2-week period during
which the dose of Irbesartan was either gradually increased
or decreased as appropriate for the following treatment
dose. If there is no response of protein damage by
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Irbesartan treatment or the response is stable and inde-
pendent of Irbesartan dose, no crossover effect is expected.
There were significant carryover effects for plasma protein
CML, CEL, MG-H1, PENT and 3-NT and urinary flux of
CEL. The effect of Irbesartan on protein damage markers
was generally not dose-dependent and hence carryover
effects are likely linked to the duration of Irbesartan
treatment than difference in dose. This indicates that there
are on-going changes in the formation and removal of
damaged proteins proteolysis after 10 weeks of treatment
that are likely linked to the long-term changes in renal
structure and function associated with prolonged treatment
with Irbesartan. In future crossover studies of this type, it
will be important to include washout periods between each
dosing period to eliminate carryover effects where ethically
justifiable. A washout period of 3–4 half-lives of the
affected marker is typical and for damage to albumin in
plasma the washout period would be 8–11 weeks from
metabolic considerations. Nevertheless, re-examination of
protein damage markers in the first treatment period where
carryover effects do not apply, there remained significant
effects of protein damage markers in plasma protein and
urine.
This study provides novel insights on the effect of
Irbesartan on protein damage in DN provided by compre-
hensive assessment of glycation, oxidation and nitration
adducts by LC–MS/MS. Previous studies of effect of
Irbesartan on protein damage markers have been per-
formed. Serum ‘‘AGE peptides’’, a fluorescence/absor-
bance ratio of deproteinised extract, were estimated in 269
type 2 diabetic patients with microalbuminuria receiving
placebo or 300 mg o.d. Irbesartan for 2 years. No effect of
treatment was found (Persson et al. 2006). Serum protein
CML residues and total serum pentosidine were deter-
mined in 135 type 2 diabetic patients with overt nephrop-
athy after treatment with 300 mg o.d. Irbesartan or placebo
for 23 months. No significant difference was found
between treatment and placebo groups (Busch et al. 2008).
Plasma protein 3-NT residue content was estimated by
enzyme-linked immunosorbent assay (ELISA) in 20 type 2
diabetic patients treated with 300 mg o.d. Irbesartan for
1 week and then given a high fat test meal, 75 g glucose or
both. Irbesartan decreased both plasma 3-NT estimates
before, during and after the tests meals (Ceriello et al.
2005). Since the estimates of plasma 3-NT by the custom
ELISA used were 50–100 higher than expected values
(Rabbani and Thornalley 2008), the estimates and changes
of plasma 3-NT residue content of this study are insecure.
The effect of Irbesartan on putative glomerular filtration
retention of glycated and oxidised albumin found in this
study is unprecedented and merits further investigation in
future studies. A major weakness of previous studies was
the assay methodology and also lack of estimates of the
major AGE, MG-H1, and urinary AGEs. Where analytical
methods were secure, as in the study of Busch et al. (2008),
no comparison of Irbesartan effect can be made due to the
difference in duration of Irbesartan treatment.
In summary, changes found in plasma protein damage
and urinary free adduct excretion of diabetic patients
receiving Irbesartan therapy herein are consistent with
decreased exposure to protein damage by methylglyoxal,
glyoxal and reactive nitrating species and the tightening of
the glomerular filtration barrier.
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